Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
May have a role in the regulation of spermatogenesis.. Additionally we are shipping PD-1 Antibodies (653) and PD-1 Proteins (91) and many more products for this protein.
Showing 4 out of 24 products:
Human PD-1 ELISA Kit for Sandwich ELISA - ABIN417517
Li, Zhou, Li, Sang, Han, Lv, Zhao, Li, Liu et al.: Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus ... in Oncotarget 2017
Human PD-1 ELISA Kit for Sandwich ELISA - ABIN2703394
Yanaba, Hayashi, Yoshihara, Nakagawa: Serum levels of soluble programmed death-1 and programmed death ligand-1 in systemic sclerosis: Association with extent of skin sclerosis. in The Journal of dermatology 2016
Higher PD-1 expression was found in chronic rhinosinusitis with nasal polyps than in nasal tissue from controls. This was associated with disease severity and tissue IL-5 (show IL5 ELISA Kits) expression but unrelated to the patients' atopy status
we find PD-1+ lymphocytes in prostate cancer tumors to be an independent negative prognostic marker in post-prostatectomy hormone naive patients.
PD-1 appears to plays a critical role in mediating NK cell exhaustion. The existence of this negative checkpoint fine-tuning NK activation highlights the possibility that manipulation of the PD-1 pathway may be a strategy for circumventing tumor escape not only from the T cell-, but also the NK-cell mediated immune surveillance.
Higher PD-1 positivity is associated with small-cell-predominant cutaneous ENKTL. However, PD-1 expression has no prognostic value in cutaneous ENKTL
PD-1 polymorphism is associated with response to therapy in hepatitis B virus-related hepatocellular carcinoma.
Many studies have shown efficacy of blocking PD-1 or PD-L1 (show CD274 ELISA Kits) with specific antibodies like pembrolizumab or atezulizumab. In breast cancer, potential response was demonstrated in metastatic triple-negative breast cancers. [review]
Studied role of programmed death-1 receptor (PD-1) and programmed death-1 receptor-ligand (PD-L1 (show CD274 ELISA Kits)) in prognosis of renal cell carcinoma. PD-1 was shown not to be a prognostic marker, while prognostic value of PD-L1 (show CD274 ELISA Kits) is unclear.
Pancreatic cancer patients with high PD-1 expression and dense stroma had a better overall survival, while patients with low PD-1 expression and moderate stroma showed worst outcome.
To test the in vivo activity of REGN2810, which does not cross-react with murine PD-1, knock-in mice were generated to express a hybrid protein containing the extracellular domain of human PD-1, and transmembrane and intracellular domains of mouse PD-1
The increased frequency of PD-1(+) and TIM-3 (show HAVCR2 ELISA Kits)(+) CD8 (show CD8A ELISA Kits)(+) TILs was inversely correlated with clinical outcome of cetuximab therapy. These results provide us with an insight into understanding dysfunction of CD8 (show CD8A ELISA Kits)+ T cells induced by PD-1 and TIM-3 (show HAVCR2 ELISA Kits) in the TME during cetuximab therapy as well as provide a rationale to combine cetuximab therapy with blockade of PD-1 and/or TIM-3 (show HAVCR2 ELISA Kits) to improve clinical outcome for HNSCC patients.
The combination of tumor vaccination to induce high avidity tumor specific T cell responses and PD-1 blockade synergises to provide tumor therapy and 85% survival in the aggressive B16 melanoma model.
Blockade of PD-1 with monoclonal antibody may be an effective treatment during the postoperative period for restoring surgery-induced immunosuppression.
Data suggest that genetic or environmental factors that even moderately affect the expression of both PD-1 and FoxP3 (show FOXP3 ELISA Kits) can cause life-threatening autoimmune diseases by disrupting the T-cell homeostasis.
Data (including data from studies in transgenic/knockout mice) suggest that T-cell expression of Mirn155 is required to limit melanoma growth; miR (show MLXIP ELISA Kits)-155, Pdcd1, Pdcd1l1 (show CD274 ELISA Kits), and Ctla4 (show CTLA4 ELISA Kits) appear to regulate overlapping pathways promoting antitumor immunity. [Mirn155 = microRNA 155; Pdcd1 = programmed cell death 1 protein; Pdcd1l1 (show CD274 ELISA Kits) = programmed cell death 1 ligand 1 (show CD274 ELISA Kits) protein; Ctla4 (show CTLA4 ELISA Kits) = cytotoxic T-lymphocyte-associated protein 4 (show CTLA4 ELISA Kits)]
PD-1 plays a vital role in brain inflammation via regulation of Fgl-2 (show FGL2 ELISA Kits) after ICH (show ACE ELISA Kits), and that manipulation of PD-1 might be a promising therapeutical target in ICH (show ACE ELISA Kits).
We identified PD-1 to be specifically expressed in PLZF(+) ILCp and revealed that the timing and order of expression of the transcription factors NFIL3 (show NFIL3 ELISA Kits), ID2, and TCF-1 (show HNF1A ELISA Kits) was critical. Importantly, induction of ILC (show CCL27 ELISA Kits) lineage commitment required only transient expression of NFIL3 (show NFIL3 ELISA Kits) prior to ID2 and TCF-1 (show HNF1A ELISA Kits) expression.
The identification of the role for PD-1 in regulating B cell-dependent antitumor immunity to Tn antigen highlights an opportunity to develop new therapeutic strategies targeting tumor-associated carbohydrate antigens
These findings suggest that PD-1 pathway blockade may reverse adaptive immune resistance following cyclic dinucleotide treatment, enhancing both local and systemic antitumor immunity.
data suggest that increased expression of checkpoint blockade molecules PD-1 and CTLA-4 (show CTLA4 ELISA Kits) on donor T cells is not sufficient to prevent GvHD, and that cooperation between checkpoint blockade signaling by host cells and donor Tregs is necessary to limit GvHD in allo-HSCT recipients
Data show that CTLA-4 (show CTLA4 ELISA Kits)(+)PD-1(-) memory CD4 (show CD4 ELISA Kits)(+) T cells, which share phenotypic markers with regulatory T cells, were enriched in SIV DNA in blood, lymph nodes (LN), spleen, and gut (show GUSB ELISA Kits), and contained replication-competent and infectious virus.
Compared to before immunosuppression, PD-1 expression increased at reactivation. Increased T cells before zoster is likely due to virus reactivation.
A PD-1(high) phenotype is associated with accelerated in vivo CD8 (show CD8A ELISA Kits) T cell turnover in SIV-infections, especially within the SIV-specific CD8 (show CD8A ELISA Kits) T cell pool.
High levels of PD-1 expression on CD4 (show CD4 ELISA Kits)(+) T cells in lymph nodes of rhesus macaques can serve as a valuable marker to identify T follicular helper cells.
Data indicate that PD-1 expression is increased as a result of T cell activation during a primary immune response as well as during persistent immune activation in macaques.
PD-1 can serve as a sensitive indicator of persistent, low-level virus replication
This gene encodes a cell surface membrane protein of the immunoglobulin superfamily. This protein is expressed in pro-B-cells and is thought to play a role in their differentiation. In mice, expression of this gene is induced in the thymus when anti-CD3 antibodies are injected and large numbers of thymocytes undergo apoptosis. Mice deficient for this gene bred on a BALB/c background developed dilated cardiomyopathy and died from congestive heart failure. These studies suggest that this gene product may also be important in T cell function and contribute to the prevention of autoimmune diseases.
programmed cell death protein 1
, protein PD-1
, programmed cell death 1
, programmed death 1